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Mast cells are primary players in immune and inflammatory diseases. In the brain, mast
cells are located at the brain side of the blood brain barrier (BBB) exerting a crucial
role in protecting the brain from xenobiotic invasion. Furthermore, recent advances
in neuroscience indicate mast cells may play an important role in glial cell-neuron
communication through the release of mediators, including histamine. Interestingly,
brain mast cells contain not only 50% of the brain histamine but also hormones,
proteases and lipids or amine mediators; and cell degranulation may be triggered
by different stimuli activating membrane bound receptors including the four types of
histaminergic receptors. Among hormones, mast cells can store thyroid hormone (T3)
and express membrane-bound thyroid stimulating hormone receptors (TSHRs), thus
suggesting from one side that thyroid function may affect mast cells function, from
the other that mast cell degranulation may impact on thyroid function. In this respect,
the research on hormones in mast cells is scarce. Recent pharmacological evidence
indicates the existence of a non-genomic portion of the thyroid secretion including thyroid
hormone metabolites. Among which the 3,5 diiodothyronine (3,5-T2), 3-iodothyroanamine
(T1AM) and 3-iodothyroacetic acid (TA1) are the most studied. All these compounds
are endogenously occurring and found to be increased in inflammatory-based diseases
involving mast cells. T1AM and TA1 induce, as T3, neuroprotective effects and itch
but also hyperalgesia in rodents with a mechanism largely unknown but mediated
by the release of histamine. Due to the rapid onset of their effectiveness they may
trigger histamine release from a cell where it is “ready-to-be released,” i.e., mast cells.
Following a very thin path which passes through old experimental and clinical evidence,
at the light of novel acquisitions on endogenous T3 metabolites, we aim to stimulate
the attention on the possibility that mast cell histamine may be the connector of a
novel (neuro) endocrine pathway linking the thyroid with mast cells.
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BACKGROUND
Mast cells are ubiquitous cells of hematopoietic origin, disseminated in the periphery and
in the nervous system. In the brain, mast cells are few in number, ideally located to the
meninges and perivascular area on the brain side of the blood-brain barrier (BBB), a strategic
localization to initiate the detoxification of xenobiotics and/or vascular and immunological effects.
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In most species studied, mast cells show a typical localization
allowing an ideal interaction with neurons. The mast cell
population of the brain is not static and it increases in
numbers, distribution and activation in response to a variety
of environmental stimuli that are associated with altered
behaviors and physio-pathological conditions (Cirulli et al.,
1998). Furthermore, emerging experimental evidence indicates
that mast cells play pivotal roles in directing brain cell
differentiation and plasticity including sexual maturation and
behavior (Lenz et al., 2018) and in neuroprotection. In respect
of this latter, stabilization of mast cells might represent a novel
neuroprotective strategy during excitotoxicity (Ocak et al., 2018).
The understanding of the mechanisms underlying the roles
of mast cells in the brain is one of the challenges of the
modern neurosciences. The hope is that the definition of such
issues may help to comprehend how the mismatching of pro-
inflammatory/anti-inflammatory factors levels, among which
those derived from mast cells, may drive behaviors and neuron
activation/survival possibly indicating novel drug targets. The
relationship between mast cells and neurons is also reproduced
in somatosensory neurons.
Irrespective of their tissue distribution, the characteristic
feature of mast cells is the presence of cytoplasmic
secretory granules which, upon activation, spread in the
microenvironment lipid mediators, amines and hormones other
than proteoglycans including heparin. Actually, the composition
of mast cell granules shows some kind of heterogeneity
depending on their tissue localization (Beil et al., 2000) and it
looks that the presence of charged compounds in the granules is
essential for the storage of other mediators (Grujic et al., 2013).
As to say that there is a sort of chemical essential requisite for
filling mast cell granules. Irrespective of this, mast cell granules
always contain histamine, a charged amine which can be secreted
together with the other mediators.
Sporadic evidence indicates that cells of the immune system,
including mast cells can synthesize and store hormones among
which are thyroid stimulating hormone (TSH) and the thyroid
hormone T3 (Csaba and Pállinger, 2009a,b; Thangam et al.,
2018). T3 levels were found increased following cell exposure
to low histamine concentrations (Csaba and Pállinger, 2009a).
Furthermore, evidence also indicates that mast cells express
T3 receptors and that tissue mast cells population increased in
hypothyroidism (Siebler et al., 2002), thus suggesting that the
health or sick thyroid could condition mast cell hormone levels
and/or that mast cells may represent an alternative source of
packaged T3 locally deliverable (Thangam et al., 2018). Actually,
even if evidence that T3 content decreased in peritonealmast cells
from hypothyroid rats (Csaba, 2014), it could further sustain this
dual role of mast cells, though a definitive proof of this duality is
lacking. In this respect, the progress in understanding the roles of
T3 metabolites might open a new scenario.
MAST CELLS AND THE THYROID
The potential relationship, if any, between the thyroid and
mast cells is certainly complex and likely two-fold. There is
evidence that T3 effects can be modulated by mast cells, and
that mast cells can modulate thyroid function. This interaction is
clinically relevant in autoimmune disorders such as rheumatoid
arthritis or intestinal inflammatory diseases (Costela-Ruiz et al.,
2018) or in autoimmune thyroiditis disease such as chronic
urticaria, characterized by recurrent episodes of mast cell-driven
wheal and flare-type skin reactions, as well as in Grave’s and
Hashimoto disease (Ruggeri et al., 2013). In patients with
chronic urticaria and angioedema, the presence of thyroid
autoantibodies (Leznoff et al., 1983) and IgE antibodies against
thyroid peroxidase were identified. By binding on the surface
of mast cells these anti-TPO-IgE autoantibodies cause mast cell
activation and degranulation, thus playing an active role in
the pathogenesis of chronic urticarial (Altrichter et al., 2011).
Mast cells also play a pivotal role in a complication associated
to Grave’s disease. van Steensel et al. (2012) demonstrated
that in patients with Grave’s ophthalmopathy, the number
of mast cells in orbital tissue increased and these cells were
capable to activate, through the PDGF pathway, the orbital
fibroblast causing the onset of ophthalmopathy. These data
suggest mast cells not only as regulators of fibroblast activation,
but also as a possible therapeutic target (van Steensel et al.,
2012). In fact, in a small cohort of patients, a little clinical
improvement after treatment with cetirizine was observed
(Lauer et al., 2008). Another interaction between thyroid and
mast cells takes place in the bone and in particular, in bone
remodeling and endochondral bone formation. The effect of
thyroid on these processes are well known but the specific
mechanism is partially elucidated. T3 exerts direct actions
on chondrocyte growth and mast cells located in the bone
marrow closed to epiphyseal plate are able to interact with
osteoblasts and chondrocytes were found involved in processes
that modify cartilage matrix and influence mineralization,
further supporting the link between thyroid function and
mast cells in bone metabolism. In fact, the number and the
distribution of bone marrow-derived mast cells was found
influenced by the thyroid status. Interestingly, bone marrow
mast cells express thyroid hormone receptors with cytoplasmic
localization which limits receptor trafficking towards the nuclei.
Interestingly, such evidence indicates that mast cells represent
a conjunction ring between T3 and bone remodeling and
opens to non-genomic effects of T3 in bone metabolism and
differentiation (Siebler et al., 2002). Data identifying an influence
of mast cells on the thyroid support the bivalence of the
relationship between thyroid and mast cells. Rocchi et al. (2007)
demonstrated a specific role of mast cells on thyroid function
in non-thyroidal illness (NTI). NTI are defined as changes of
the hypothalamic—pituitary—thyroid axis in patients suffering
from illnesses not primarily originating in the thyroid. These
clinical conditions are characterized by: (a) decreased T3 levels;
(b) decreased T4 due to a reduced binding capacity and/or
affinity of serum carrier proteins for T4; and (c) inappropriately
normal or low levels of TSHwith respect to the decreased thyroid
hormone levels (Faber et al., 1981; Kaptein et al., 1982; Docter
et al., 1993; Wilcox et al., 1994). In a mouse model of NTI, a
specific link between mast cells and bacterial infection-induced
hypothyroidism was also found. This study identifies a role for
mast cells as sensors capable of controlling the homeostatic
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FIGURE 1 | Schematic representation of thyroid and mast cell connections. The hypothalamus, throughout the release of the TSH, stimulates mast cells increasing
the T3 content. T3 is co-stored with histamine in mast cell granules or is degraded to T1AM and/or TA1. T1AM and TA1 derived from circulation or produced inside
mast cells trigger mast cell degranulation releasing T3 and histamine which mediates pain, itch and central effects including neuroprotection/neuroinflammation.
Thyroid stimulating hormone (TSH); TSH receptor (TSHR); thyroid hormones (T3, T4); 3-iodothyronamine (T1AM); 3-iodothyroacetic acid (TA1); monoamine
oxidases (MAO).
responsiveness of the hypothalamus—pituitary—thyroid axis
through the activation of specific crystallizing fragment (Fc)
receptors (FCgR3). The lack of response in mast cells
deficient mice confirmed the pivotal role of these cells
(Rocchi et al., 2007).
This link might be stronger in case of heterogeneous diseases
related to abnormal mast cell activation or increased tissue
mast cell number, including cutaneous and/or their systemic
presentations whose diagnosis is based on the monitoring of
serum tryptase, elevated 24-h urinary histamine metabolite
(methylhistamine). Among these is mastocytosis, a pathology
characterized by increased tissue mast cell number. Among
clinical manifestations of mastocytosis are dermatological
symptoms, including itch and urticaria, and also neurological
and psychiatric disorders (Georgin-Lavialle et al., 2016) mainly
supported by increased histamine levels.
HISTAMINE AND THE THYROID
Histamine is essentially a pro-inflammatory mediator and if a
low-grade inflammation is considered to be beneficial, sustained
inflammation may generate abnormal cell behaviors. Histamine
has different fate and effects in neuronal and not neuronal
tissues. In not neural tissues, histamine deriving from mast
cells, basophiles or enterochromaffin-like cells is recognized
as a charged amine which enters in the calculation of the
diamine (polyamine) tissue levels and it is implicated in local
inflammation, pain, itch and vasodilatation. In periphery it
is preferentially scavenged by the diamine oxidase (DAO)
producing hydrogen peroxide and promotes its effects activating
mainly the for types of receptors. In the central nervous system,
histamine is produced and released by histaminergic neurons
and by mast cells (Li et al., 2018) and the discrimination of the
two possible sources can be achieved using genetic models or
stabilizing pharmacologically mast cells. In the central nervous
system, histamine is not considered a polyamine, the DAO is
absent, and the enzymes involved in its metabolism, include
the histamine methyl-transferase and the type B monoamine
oxidase (MAO-B). Brain histamine is retained as a signal of the
cell-to-cell communication with particular respect to microglia
and neurons and the modulation of the brain histaminergic
system may be afforded by drugs promoting histamine release
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acting at receptors, working somehow as ‘‘neuromodulators’’
or by triggering mast cell degranulation. To note, mast cells
possess receptors for aminergic mediators including the four
types of histaminergic receptors, a condition which allows
histamine to establish a sort of paracrine control on mast cells
degranulation (Thangam et al., 2018). Thus, the role of mast cells,
where histamine is ready-to-be released, may became relevant
in generating high local histamine levels and immune-mediated
inflammatory milieus (Fang et al., 2014).
Brain histamine (neuronal and not neuronal) is part of the
mediators involved in the control of hypothalamic governed
behaviors and it is also endowed of neuroprotective effects
against excitotoxic damage (Kukko-Lukjanov et al., 2006).
Furthermore, brain histamine is also part of the mechanisms of
the neuroprotection offered by T3 metabolites (Cao et al., 2009;
Laurino et al., 2018a,b). On the other hand, it is well assessed that
histamine also controls the release of TSH (Roberts and Calcutt,
1983), a finding potentially linking the histaminergic system to
the control of thyroid function. Actually, data regarding the effect
of some histaminergic type 2 receptor antagonists on patient
T3 serum levels seem to support, at least in part, the role of
histamine in the control of TSH (Pasquali et al., 1981; Corinaldesi
et al., 1987), thus suggesting a possible role of histamine in
thyroxine regulation.
The T3 levels are critical regulators of the prenatal and
neonatal development of the nervous system and of post-natal
brain plasticity. A part of the well-known role of T3 on neurons,
T3 is also a critical regulator of glial cell functions with not only
genomic but also non-genomic mechanisms. Glial cells, as mast
cells, express T3 transporters (Mori et al., 2015).
Histamine levels were found high during the embryonic
brain development (Pearce and Schanberg, 1969) and Sabria
et al. (1987) reported T3 as possible candidate for controlling
brain mast cells number and, consequently, the levels of brain
histamine during development. Till now there is no evidence
that brain mast cells may contain T3 but there are evidence that
T3 metabolites activate the histaminergic system in the brain as
well as in periphery (Laurino et al., 2018a,b).
Upadhyaya et al. (1993) demonstrated that in L-thyroxine-
treated rats, histamine levels were found increased in the
hypothalamus, thalamus and cortex of the rats, and that there
was a positive correlation between circulating T3 and T4 levels
and histamine. Csaba and Pállinger (2009a) demonstrated that
very low histamine concentrations, not active on pain and
inflammation, increased T3 mast cell content.
Inflammatory-based diseases of the thyroid are named
thyroiditis. Banovac and De Forteza (1992) demonstrated that
mast cells degranulation plays a pivotal role in promoting the
early stage of thyroiditis. More recently, experimental data from
Visciano et al. (2015) demonstrated that mast cells histamine
promotes a pro-tumorogenic effect on the thyroid and, in
thyroid tumors and in experimental secondary hypothyroidism
as, the mast cell population of the gland increased (Melander
et al., 1971; Melillo et al., 2010), thus increasing histamine
content of the gland. Furthermore, supporting the role of
inflammation and autoimmune diseases in thyroid cancers,
evidence indicate that mast cells play a pro-tumorogenic role
in human thyroid cancer promoting neoangiogenesis and
invasiveness (Melillo et al., 2010). Furthermore, mast cell
number increased in thyroid cancer particularly in the follicular
variant of papillary thyroid carcinoma, where their localization
could represent a diagnostic marker of this kind of tumor
(Proietti et al., 2011). Furthermore, assuming that mast cells
of the healthy or sick thyroids behave as peritoneal mast
cells, their role would become relevant in the economy of T3
(Melander et al., 1975).
Among thyroid diseases manifestations are skin symptoms
among which are including chronic urticaria, alopecia and atopic
dermatitis (Artantas et al., 2009). Interestingly, in all these
complex diseases the brain-skin connection and the pivotal
role of stress-induced mast cell degranulation has been recently
reviewed (Shimoda et al., 2010; Alexopoulos and Chrousos,
2016). In this respect, the local release of T3 or of T3 metabolites
might participate in the clinical symptoms of these kin diseases.
To note, T3 been detected in peritoneal mast cells, a finding
suggesting that these mobile cells may deliver the hormone
systemically. Furthermore, Csaba and Pállinger (2009a,b)
demonstrated that secondary to TSH receptor activation, mast
cells T3 content was found increased, without however indicating
the mechanism. Unfortunately, the knowledge on the physio-
pathological significance of T3 presence in peritoneal mast
cells did not improve further from the evidence of Csaba
and Pállinger (2009a,b). Thus, the possibility that mast cells
may function as an ‘‘alternative’’ thyroid gland remains only
a hypothesis.
THYROID HORMONE METABOLITES AND
HISTAMINE
Recent experimental evidence suggest that T3 metabolism
generates compounds that are not only able to reproduce similar
but also opposite effects to those of T3 without activating nuclear
receptors. T3 metabolisms is carried out by decarboxylase,
deiodinases and MAOs which can work on T3 in sequence or
alternatively producing three main families of derivatives namely
thyronines, thyronamines, thyroacetic and thyropropionic acids
at different degree of iodination. To note, the activity of MAO
allows the transformation of thyronamines into thyroacetic
acids while deiodinase activity removes iodide ions without
transforming the chemical family. Despite of this, the synthetic
pathway of these compounds is not fully elucidated yet.
Interestingly, several experimental and clinical evidence
suggest that T3 metabolites may be part of the thyroid
homeostasis and that they could be implicated in thyroid
diseases. Among the main derivatives studied are the
3,5 diiodothyronine (3,5-T2), the 3-iodothyronamine (T1AM)
and 3-iodothyroacetic acid (TA1; Scanlan et al., 2004; Chiellini
et al., 2012; Galli et al., 2012; la Cour et al., 2018). All of them
were found endogenously in rodents and in humans with a
tissue distribution of T1AM and TA1 mirroring that of the
T3 (Chiellini et al., 2012). Some studies reported an increased
T1AM levels in pathological conditions including diabetes (Galli
et al., 2012) and heart failure (la Cour et al., 2018). Interestingly
enough, 3,5-T2 circulating levels were found increased in
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cirrhosis, in brain tumors and in patients with non-thyroidal
illnesses. In these latter cohort of patients, 3,5-T2 circulating
levels were found correlated with the onset of post-surgical
atrial fibrillation episodes (Dietrich et al., 2015). At the level
of the heart, Frascarelli et al. (2011) demonstrated that T1AM
exerts cardioprotective effects in an isolated rat heart model of
ischemia-reperfusion injury, as to say that thyroid function on
the heart is complex involving T3 and T3 metabolites.
Also, pharmacological evidence indicate T1AM is a regulator
of body temperature (Scanlan et al., 2004) ofmice feeding (Manni
et al., 2012), it promotes memory acquisition and retrieval
(Manni et al., 2013; Bellusci et al., 2017), it is anti-amnestic
(Laurino et al., 2017), induces hyperalgesia and also has the
potential to behave as an anti-obesity drug (Assadi-Porter et al.,
2018). T1AM has a short half-life being rapidly degraded to its
oxidative metabolite, the 3-iodothyroacetic acid (TA1). Since the
oxidative deamination is carried on by MAO activity, TA1 is
considered part of the pharmacological profile of T1AM, being
MAO ubiquitously expressed (Laurino et al., 2015a,b). As a
fingerprint of both T1AM and TA1, pharmacological effects
is the rapid onset of their rapid onset, within 15 min from
administration. Furthermore, they are active at very low doses
always showing inverted bell-shaped dose-effect curves.
Laurino et al. (2015a,b, 2018a,b) demonstrated that T1AM
and TA1 behavioral effects were dependent on the activation of
the brain or peripheral histaminergic system, with a mechanism
which, however, remains to be clarified.
T1AM is a multi-target compound (Bräunig et al., 2018)
able to interact at G-protein coupled receptors, including
the trace amine associated receptors, and also ion channels
but not with T3 receptors. However, if we accept the trace
amine associated receptors, the affinity of T1AM for such
targets is much lower than its in vivo potency, thus making
unlikely the participation of such targets in T1AM in vivo
effects. Notwithstanding this, all the behavioral effects of T1AM
(and of TA1) including the pro-learning effect, hyperalgesia
and the neuroprotection were abolished by anti-histaminergic
drug treatment of mice including type 1 receptor antagonists,
a strategy which however does not allow to recognize the
source of histamine which consists of neuronal and mast cell
derived histamine. Considering T3 metabolites can pass the
BBB reproducing most of the effects described for histamine,
the timing of their effects, the localization of brain mast
cells at the BBB, the possibility that mast cells, other than
histaminergic neurons, are among the targets of T3 metabolites
become a plausible hypothesis. This source of histamine would
also explain the bell-shaped curves observed following T1AM
(and TA1) administration where a slow re-synthesis does not
allow a fast refilling of the granules. Furthermore, the link
between T3 metabolites and their possible degranulating effect
on mast cells might be more stringent in the case of peripheral
histamine-mediated effects. In fact, T3 supplementation is one
among the cause of systemic itch (Reamy et al., 2011) and
pruritus is one among the clinical symptoms of hyperthyroidism
(Ward and Bernhard, 2005). Similarly, T3 metabolites induce
itch (Laurino et al., 2015a,b) activating, histamine-dependent,
pERK in the dorsal root ganglia. This pathway is considered
selective for mast cell-derived histamine-induced itch sensation
(Dong and Dong, 2018; Huang et al., 2018). Even if the
definitive proof is lacking, T3 metabolites, by activating
mast cells, might be the mediators of T3-induced itch.
Furthermore, confirming that itch and pain sensation have
some common neuronal pathways, T1AM and TA1 also
induce histamine-dependent hyperalgesia to thermal stimuli
(Manni et al., 2013), a condition typically activating mast cells
(Zhang et al., 2012).
In conclusion, the relationship between the thyroid and mast
cells is scarcely studied but we strongly believe it merits to be
investigated further from the clinical and mechanistic point of
view. In this respect in this article, we tried to point the attention
on the non-canonical portion of the thyroid secretion constituted
by T3metabolites, as possible activators of mast cells and releaser
of histamine (Figure 1).
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